Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Salvage Radiotherapy for Prostate Cancer: The Role of Androgen Deprivation Therapy
The addition of short-course ADT to salvage radiotherapy was associated with improved outcomes.
Neoadjuvant Therapy Sequencing May Improve Outcome in Rectal Cancer
Disease-free survival at 3 years with a total neoadjuvant approach was similar to that for historical controls treated with conventional chemoradiotherapy followed by surgery.
Artificial Intelligence and Improved Drugs: Another Big Step Forward
Designer “mini-antibodies” constitute a new drug class.
Recurrence Rates for Women with Estrogen-Associated Venous Thromboembolism
A low risk of recurrence was noted following discontinuation of anticoagulation.
Sintilimab plus Chemotherapy for First-Line Treatment of Metastatic Esophageal Cancer
Survival was superior with the addition of sintilimab.
New Prevalence Data on Monoclonal Gammopathies
With sensitive detection techniques, >10% of people older than 50 had monoclonal gammopathy of undetermined significance.
Underrecognition of Symptoms Caused by Breast Radiation Therapy
Radiation oncologists underrecognized common symptoms of acute toxicity in more than half of patients, and more often in Black patients than white patients.
BRCA1 and BRCA2: Risk Beyond Breast and Ovarian Cancer
Data from Japan suggest that pathogenic variants are associated with increased risk for a broad group of malignancies.
Do Advance Directives Undermine Advance Care Planning?
In this qualitative study, patients sometimes viewed advance directives as a substitute for, rather than an adjunct to, goals-of-care discussions.